Evidence map›Paper›PMID 38394670›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2024

Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and Solutions.

Serena Omo-Lamai, Marco E Zamora, Manthan N Patel, Jichuan Wu, Jia Nong, Zhicheng Wang, Alina Peshkova, Aparajeeta Majumder, Jilian R Melamed, Liam S Chase and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
39.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 88 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  12. Article
  13. Tissue-specific gene delivery approaches.Bioengineering & translational medicine · 2026
    Review
  14. Article
  15. Article
  16. Equip your vehicle for the right terrain: Using features of local pathology to guide engineering of targeted drug delivery systems.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  17. Review
  18. Article
  19. Article
  20. Design of cationic ionizable lipids for the delivery of therapeutic nucleic acids.Molecular therapy. Methods & clinical development · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Serena Omo-LamaiDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0003-3305-4585
Marco E ZamoraSchool of Biomedical Engineering, Drexel University, Philadelphia, PA, 19104, USA.
Manthan N PatelDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Jichuan WuDivision of Pulmonary Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Jia NongDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Zhicheng WangDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Alina PeshkovaDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Aparajeeta MajumderDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Jilian R MelamedDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Liam S ChaseDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Eno-Obong EssienDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Drew WeissmanDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Vladimir R MuzykantovDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Oscar A Marcos-ContrerasDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Jacob W MyersonDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Jacob S BrennerDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0001-8437-0161
Translational Therapeutics (United States) · USUniversity of Pennsylvania · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
Vascular Targeting of Nanocarriers for RNAR01HL155106 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R, WEISSMAN, DREW · 2021 to 2024
$3.1M
Dual drug delivery to lung/blood interface in respiratory infections.R01HL157189 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2021 to 2024
$2.9M
mRNA-LNPs for ARDSR01HL164594 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Jacob Brenner, Hamideh Parhiz · 2023 to 2026
$2.7M
Controlling complement to unleash nanomedicine for acute critical illnessesR01HL160694 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BRENNER, JACOB, MUZYKANTOV, VLADIMIR R · 2022 to 2025
$2.7M
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillariesR01HL153510 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BRENNER, JACOB · 2020 to 2024
$2.0M
RBC-mediated mopping of cytokines for the treatment of pneumoniaR21AI166778 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BRENNER, JACOB · 2021 to 2022
$447k
Nanoscale drug carriers for the treatment of Acute Respiratory Distress Syndrome (ARDS).F31HL154662 · NHLBI · DREXEL UNIVERSITY · PI ZAMORA, MARCO E · 2020 to 2023
$186k
Abramson Cancer Center NCI 016520American Heart Association 23PRE1014444National Research Service Award F31HL154662NCI NIH HHS P30 CA016520NHLBI NIH HHS F31 HL154662NHLBI NIH HHS R01 HL153510NHLBI NIH HHS R01 HL155106NHLBI NIH HHS R01 HL157189NHLBI NIH HHS R01 HL160694NHLBI NIH HHS R01 HL164594NIAID NIH HHS R21 AI166778Pharmaceutical Research and Manufacturers of America Foundation 2023 PFDL 1008128
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) have become the dominant drug delivery technology in industry, holding the promise to deliver RNA to up or down-regulate any protein of interest. LNPs have mostly been targeted to specific cell types or organs by physicochemical targeting in which LNP's lipid compositions are adjusted to find mixtures with the desired tropism. Here lung-tropic LNPs are examined, whose organ tropism derives from containing either a cationic or ionizable lipid conferring a positive zeta potential. Surprisingly, these LNPs are found to induce massive thrombosis. Such thrombosis is shown in the lungs and other organs, and it is shown that it is greatly exacerbated by pre-existing inflammation. This clotting is induced by a variety of formulations with cationic lipids, including LNPs and non-LNP nanoparticles, and even by lung-tropic ionizable lipids that do not have a permanent cationic charge. The mechanism depends on the LNPs binding to and then changing the conformation of fibrinogen, which then activates platelets and thrombin. Based on these mechanisms, multiple solutions are engineered that enable positively charged LNPs to target the lungs while ameliorating thrombosis. The findings illustrate how physicochemical targeting approaches must be investigated early for risks and re-engineered with a careful understanding of biological mechanisms.

Indexed as

Blood CoagulationLipidsLungNanoparticlesThrombosisAnimalsFibrinogenHumansMiceThrombinFibrinogenLipidsThrombindrug deliverylipid nanoparticlesnanomedicineside effectsthrombosis

Identifiers

PMID38394670
PMCPMC11209818
OpenAlexW4392092523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.